ALK, ALK receptor tyrosine kinase, 238

N. diseases: 519; N. variants: 41
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma 		0.700 CausalMutation disease CGI
CUI: C0152013
Disease: Adenocarcinoma of lung (disorder)
Adenocarcinoma of lung (disorder) 		0.700 CausalMutation disease CGI
CUI: C0334121
Disease: Inflammatory Myofibroblastic Tumor
Inflammatory Myofibroblastic Tumor 		0.700 CausalMutation disease CGI
CUI: C0006118
Disease: Brain Neoplasms
Brain Neoplasms 		0.610 CausalMutation group CGI
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma 		0.600 CausalMutation disease CGI
CUI: C0206180
Disease: Ki-1+ Anaplastic Large Cell Lymphoma
Ki-1+ Anaplastic Large Cell Lymphoma 		0.600 CausalMutation disease CGI
CUI: C2751681
Disease: NEUROBLASTOMA, SUSCEPTIBILITY TO, 3
NEUROBLASTOMA, SUSCEPTIBILITY TO, 3 		0.600 GeneticVariation disease CLINVAR
CUI: C2751681
Disease: NEUROBLASTOMA, SUSCEPTIBILITY TO, 3
NEUROBLASTOMA, SUSCEPTIBILITY TO, 3 		0.600 CausalMutation disease CLINVAR
CUI: C2751681
Disease: NEUROBLASTOMA, SUSCEPTIBILITY TO, 3
NEUROBLASTOMA, SUSCEPTIBILITY TO, 3 		0.600 SusceptibilityMutation disease CLINVAR
CUI: C0035412
Disease: Rhabdomyosarcoma
Rhabdomyosarcoma 		0.500 CausalMutation disease CGI
CUI: C0153633
Disease: Malignant neoplasm of brain
Malignant neoplasm of brain 		0.500 CausalMutation disease CGI
CUI: C3899155
Disease: hereditary neuroblastoma
hereditary neuroblastoma 		0.400 Biomarker disease GENOMICS_ENGLAND
CUI: C0025202
Disease: melanoma
melanoma 		0.390 CausalMutation disease CGI
CUI: C1333294
Disease: ALK positive large B-cell lymphoma
ALK positive large B-cell lymphoma 		0.360 FusionGene disease ORPHANET
CUI: C0017638
Disease: Glioma
Glioma 		0.320 CausalMutation disease CGI
CUI: C1335177
Disease: Ovarian Serous Adenocarcinoma
Ovarian Serous Adenocarcinoma 		0.310 GeneticVariation disease UNIPROT
CUI: C0151779
Disease: Cutaneous Melanoma
Cutaneous Melanoma 		0.300 CausalMutation disease CGI
CUI: C0027766
Disease: Nervous System Neoplasms
Nervous System Neoplasms 		0.100 Biomarker group HPO
CUI: C0241577
Disease: Elevated urinary catecholamines
Elevated urinary catecholamines 		0.100 Biomarker phenotype HPO
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma 		0.600 GeneticVariation disease BEFREE <b>Background:</b> A total of 2%-7% of non-small cell lung cancer (NSCLC) patients have anaplastic lymphoma kinase (ALK) mutations. 31190983 2019
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma 		0.100 Biomarker disease BEFREE <b>Conclusion</b>: The unearthed new molecular action of brigatinib suggests that therapeutic modulation of ER stress and autophagy might represent a valid strategy to treat CRC and perhaps other ALK-negative cancers. 31410188 2019
CUI: C0023530
Disease: Leukopenia
Leukopenia 		0.010 GeneticVariation disease BEFREE <b>Conclusion:</b> In patients with non-small-cell lung cancer, incidence of grade 3-4 neutropenia with ALK-targeted therapy is not significantly different compared with chemotherapy. 31116035 2019
CUI: C0027947
Disease: Neutropenia
Neutropenia 		0.010 GeneticVariation disease BEFREE <b>Conclusion:</b> In patients with non-small-cell lung cancer, incidence of grade 3-4 neutropenia with ALK-targeted therapy is not significantly different compared with chemotherapy. 31116035 2019
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma 		0.600 Biomarker disease BEFREE <b>Conclusion:</b> The above results indicated the gold nanoshell-based system would be a promising translational nano-formulation platform for effective treatment of EML4-ALK-positive NSCLC. 29774063 2018
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.100 AlteredExpression disease BEFREE <b>Introduction</b>: Brigatinib is a second-line inhibitor for the treatment of rearranged anaplastic lymphoma kinase (ALK) in lung cancer patients which has significant activity against brain metastases. 31328968 2019